A Randomized Phase II Trial of CHOP with G-CSF Support or ProMACE-CytaBOM with G-CSF Support for Treatment of Non-Hodgkin's Lymphoma

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma

H Gustafson (Tardif);S Yao;B Goldman;K Lee;C Spier;M LeBlanc;L Rimsza;JR Cernan;TM Habermann;BK Link;MJ Mauer;SL Slager;D Persky;T Miller;RI Fisher;C Ambrosone;M Briehl American Journal of Hematology 89(6):639-645;

PMid: PMID24633940 | PMC number: PMC4137041

Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate and high grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349)

DW Blayney;ML LeBlanc;T Grogan;ER Gaynor;RA Chapman;CH Spiridonidis;SA Taylor;SI Bearman;TP Miller;RI Fisher Journal of Clinical Oncology 21(13):2466-2473

Dose-intense CHOPx2 therapy of intermediate grade lymphoma -- a phase II study of the Southwest Oncology Group (SWOG)

DW Blayney;M LeBlanc;RI Fisher Blood 98(11):343a(#1448)